These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 7923250)

  • 1. Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients.
    Boiardi A; Silvani A; Ruffini PA; Rivoltini L; Parmiani G; Broggi G; Salmaggi A
    Cancer Immunol Immunother; 1994 Sep; 39(3):193-7. PubMed ID: 7923250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive immunotherapy with adherent lymphokine-activated killer (A-LAK) cells in glioblastoma multiforme.
    Munari L; Silvani A; Passerini CG; Radrizzani M; Parmiani G; Boiardi A
    J Neurosurg Sci; 1990; 34(3-4):283-8. PubMed ID: 1965907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.
    Hayes RL; Koslow M; Hiesiger EM; Hymes KB; Hochster HS; Moore EJ; Pierz DM; Chen DK; Budzilovich GN; Ransohoff J
    Cancer; 1995 Sep; 76(5):840-52. PubMed ID: 8625188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2.
    Merchant RE; Grant AJ; Merchant LH; Young HF
    Cancer; 1988 Aug; 62(4):665-71. PubMed ID: 2840186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma.
    Dillman RO; Duma CM; Ellis RA; Cornforth AN; Schiltz PM; Sharp SL; DePriest MC
    J Immunother; 2009; 32(9):914-9. PubMed ID: 19816190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma.
    Dillman RO; Duma CM; Schiltz PM; DePriest C; Ellis RA; Okamoto K; Beutel LD; De Leon C; Chico S
    J Immunother; 2004; 27(5):398-404. PubMed ID: 15314549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor.
    Merchant RE; Merchant LH; Cook SH; McVicar DW; Young HF
    Neurosurgery; 1988 Dec; 23(6):725-32. PubMed ID: 2851116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
    Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results.
    Tomita Y; Katagiri A; Saito K; Imai T; Saito T; Tanikawa T; Terunuma M; Nishiyama T; Takahashi K
    Int J Urol; 1998 Jan; 5(1):16-21. PubMed ID: 9535595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2].
    Nakano E; Iwasaki A; Seguchi T; Sugao H; Tada Y; Matsuda M; Sonoda T
    Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):395-404. PubMed ID: 2072602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.
    Yoshida S; Tanaka R; Takai N; Ono K
    Cancer Res; 1988 Sep; 48(17):5011-6. PubMed ID: 3261631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine-activated killer cells in the treatment of in-transit metastases from limb cutaneous melanoma.
    Vaglini M; Belli F; Santinami M; Arienti F; Parmiani G; Persiani L; Santoro N; Grazia Inglese M; D'Elia F; Cascinelli N
    Ann Surg Oncol; 1995 Jan; 2(1):61-70. PubMed ID: 7834457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
    Tzeng JJ; Barth RF; Clendenon NR; Gordon WA
    Cancer Res; 1990 Jul; 50(14):4338-43. PubMed ID: 2364388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors.
    Sankhla SK; Nadkarni JS; Bhagwati SN
    J Neurooncol; 1996 Feb; 27(2):133-40. PubMed ID: 8699235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma.
    Law TM; Motzer RJ; Mazumdar M; Sell KW; Walther PJ; O'Connell M; Khan A; Vlamis V; Vogelzang NJ; Bajorin DF
    Cancer; 1995 Sep; 76(5):824-32. PubMed ID: 8625186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.
    Rosenberg SA; Lotze MT; Yang JC; Topalian SL; Chang AE; Schwartzentruber DJ; Aebersold P; Leitman S; Linehan WM; Seipp CA
    J Natl Cancer Inst; 1993 Apr; 85(8):622-32. PubMed ID: 8468720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of lymphokine-activated killer cells with or without radiation therapy against malignant brain tumors.
    Nakagawa K; Kamezaki T; Shibata Y; Tsunoda T; Meguro K; Nose T
    Neurol Med Chir (Tokyo); 1995 Jan; 35(1):22-7. PubMed ID: 7700478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer.
    Gambacorti-Passerini C; Hank JA; Albertini MR; Borchert AA; Moore KH; Schiller JH; Bechhofer R; Borden EC; Storer B; Sondel PM
    J Immunother Emphasis Tumor Immunol; 1993 Jan; 13(1):43-8. PubMed ID: 8435431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional administration of lymphokine-activated killer cells can be superior to intravenous application.
    Keilholz U; Schlag P; Tilgen W; Brado B; Galm F; Görich J; Kauffmann GW; Möller P; Schneider S; Hunstein W
    Cancer; 1992 Apr; 69(8):2172-5. PubMed ID: 1544123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.